Clinical trial
A Study of Volociximab in Metastatic Melanoma
NCT00369395 · Abbott, Industry · Terminated
Key facts
| NCT number | NCT00369395 |
|---|---|
| Title | A Study of Volociximab in Metastatic Melanoma |
| Official title | A Phase 2, Open-Label, Two-Stage Study of Volociximab (M200) for the Treatment of Subjects With Metastatic Melanoma |
| Lead sponsor | Abbott, Industry |
| Collaborators | Biogen Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | volociximab |
| Enrollment | 19 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Aug 29, 2006 |
| Last update posted | Apr 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: